Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 9128 results

  1. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments

    Awaiting development Reference number: GID-TA12461 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Venglustat for treating Fabry disease

    Awaiting development Reference number: GID-TA12452 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-HTG10902 Expected publication date: TBC

    HealthTech guidance
    In development

  6. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-HTG10898 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  9. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  10. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  12. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  14. Neurostimulation of lumbar multifidus for refractory chronic low back pain with lumbar multifidus dysfunction

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  15. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]

    Deferred Reference number: GID-TA10905

    Technology appraisal guidance
    Deferred